# GlaxoSmithKline and Sanofi to support COVAX with 200 million doses of COVID-19 vaccine

- Link: https://www.directorstalkinterviews.com/glaxosmithkline-and-sanofi-to-support-covax-with-200-million-doses-of-covid-19-vaccine/412867978
- Published: 2020-10-28T07:15:22+00:00
- Author: Amilia Stone

**[GlaxoSmithKline](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)
plc** ([LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
and Sanofi have signed a Statement of Intent with Gavi, the legal administrator 
of the COVAX Facility, a global risk-sharing mechanism for pooled procurement and
equitable distribution of eventual COVID-19 vaccines.

Sanofi and GSK intend to make available 200 million doses of their adjuvanted recombinant
protein-based COVID-19 vaccine, if approved by regulatory authorities and subject
to contract, to the COVAX Facility.  Both Companies intend to contribute to COVAX’s
ambition to ensure successful COVID-19 vaccines reach those in need, whoever they
are and wherever they live, once they obtain appropriate approvals.

> **Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur,
> said:**
> “To address a global health crisis of this magnitude, it takes unique partnerships.
> The commitment we are announcing today for the COVAX Facility can help us together
> stand a better chance of bringing the pandemic under control.  This moment also
> reflects our long-term commitment to global health and ensures our COVID-19 vaccines
> are affordable and accessible to those most at risk, everywhere in the world.”

The COVAX Facility is part of COVAX, a global collaboration of governments, global
health organizations, businesses and philanthropic organizations working to accelerate
development, production, and equitable access to COVID-19 vaccines. COVAX is co-
led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO 
and forms the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator.
More than 180 countries and economies recently signed onto the COVAX Facility to
get timely and cost-effective access to vaccines to meet the global scale of the
COVID-19 pandemic.

Through the COVAX Facility’s efforts, vaccines will be distributed in participating
countries through the WHO’s recently published Allocation Framework, and the WHO’s
Strategic Advisory Group of Experts on Immunization (SAGE) Values Framework which
has begun to frame future guidance on vaccine use. These allocation principles aim
to ensure that people in all parts of the world will get access to COVID-19 vaccines
once they are available.

**Status of the adjuvanted recombinant protein-based vaccine development**

Sanofi and GSK initiated a Phase 1/2 study on September 3 with a total of 440 subjects
enrolled, and anticipate first results in early December 2020, to support the initiation
of a pivotal Phase 3 study before the end of the year. If these data are sufficient
for licensure application, it is planned to request regulatory approval from the
first half of 2021. In parallel, the Companies are scaling up manufacturing of the
antigen and adjuvant respectively.

> **Roger Connor, President of GlaxoSmithKline Vaccines said:**
> “Since we started working on the development of COVID-19 vaccines, GSK has pledged
> to make them available to people around the world. We are proud to be working 
> with Sanofi to make this adjuvanted recombinant protein-based vaccine available
> to the countries signed up to the COVAX Facility as soon as possible – this has
> the potential to be a significant contribution to the global fight against COVID-
> 19.”

Share on:
